ABSTRACT
Reproductive performance of female pigs that do not receive sufficient colostrum from birth is permanently impaired. Whether lactocrine deficiency, reflected by low serum immunoglobulin immunocrit (iCrit), affects patterns of endometrial gene expression during the periattachment period of early pregnancy is unknown. Here, objectives were to determine effects of low iCrit at birth on the adult endometrial transcriptome on pregnancy day (PxD) 13. On the first day of postnatal life, gilts were assigned to high or low iCrit groups. Adult high (n = 8) and low (n = 7) iCrit gilts were bred (PxD 0), and humanely slaughtered on PxD 13 when tissues and fluids were collected. The endometrial transcriptome was defined for each group using mRNAseq and microRNAseq. Reads were mapped to the Sus scrofa 11.1 genome build. Mature microRNAs were annotated using miRBase 21. Differential expression was defined based on fold change (≥ ±1.5). Lactocrine deficiency did not affect corpora lutea number, uterine horn length, uterine wet weight, conceptus recovery, or uterine luminal fluid estrogen content on PxD 13. However, mRNAseq revealed 1157 differentially expressed endometrial mRNAs in high versus low iCrit gilts. Differentially expressed genes had functions related to solute transport, endometrial receptivity, and immune response. Six differentially expressed endometrial microRNAs included five predicted to target 62 differentially expressed mRNAs, affecting similar biological processes. Thus, lactocrine deficiency on the first day of postnatal life can alter uterine developmental trajectory with lasting effects on endometrial responses to pregnancy as reflected at the level of the transcriptome on PxD 13.
Subject(s)
Endometrium/metabolism , Growth Substances/deficiency , Lactation/physiology , Pregnancy, Animal , Swine , Transcriptome , Animals , Animals, Newborn , Colostrum/physiology , Embryo Implantation/drug effects , Endometrium/drug effects , Endometrium/pathology , Female , Gene Expression Regulation, Developmental/drug effects , Gestational Age , Growth Substances/pharmacology , Pregnancy , Pregnancy, Animal/genetics , Pregnancy, Animal/metabolism , Swine/genetics , Swine/metabolism , Transcriptome/drug effectsABSTRACT
The lactocrine hypothesis for maternal programming of female reproductive tract development is based on the idea that non-nutritive, milk-borne bioactive factors (MbFs), delivered from mother to offspring during nursing, play a role in determining the trajectory of development with long-term consequences in the adult. Porcine female reproductive tract development is completed postnatally, and the period during which maternal support of neonatal growth derives exclusively from colostrum/milk defines a window of opportunity for lactocrine programming of reproductive tissues. Beyond nutrition, milk serves as a delivery system for a variety of bioactive factors. Porcine relaxin is a prototypical MbF. Present in colostrum at highest concentrations at birth, relaxin is transmitted into the circulation of nursing piglets where it can act on Relaxin receptors found in neonatal female reproductive tract tissues. This process is facilitated by the physiology of the maternal-neonatal dyad and the fact that the neonatal gastrointestinal tract is open to absorb macromolecules for a period of time postnatally. Age at first nursing and duration of nursing from birth are also important for porcine female reproductive tract development. These parameters affect both the quality and quantity of colostrum consumed. Disruption of lactocrine signaling by feeding milk replacer from birth altered porcine uterine, cervical, and testicular development by postnatal Day 2. Moreover, insufficient colostrum consumption in nursing piglets can impair uterine capacity to support viable litters of optimal size in adulthood. In the pig, lactocrine signaling supports neonatal organizational events associated with normal reproductive development and may program adult uterine capacity.
Subject(s)
Colostrum/metabolism , Genitalia, Female/growth & development , Genitalia, Male/growth & development , Receptors, G-Protein-Coupled/metabolism , Receptors, Peptide/metabolism , Relaxin/metabolism , Animals , Female , Male , SwineABSTRACT
BACKGROUND: The rice gene, OsMADS45, which belongs to the MADS-box E class gene, participates in the regulation of floral development. Previous studies have revealed that ectopic expression of OsMADS45 induces early flowering and influences reduced plant height under short-day (SD) conditions. However, the regulation mechanism of OsMADS45 overexpression remains unknown. We introduce an OsMADS45 overexpression construct Ubi:OsMADS45 into TNG67 plants (an Hd1 (Heading date 1) and Ehd1 (Early heading date 1) defective rice cultivar grown in Taiwan), and we analyzed the expression patterns of various floral regulators to understand the regulation pathways affected by OsMADS45 expression. RESULTS: The transgenic rice exhibit a heading date approximately 40 days earlier than that observed in TNG67 plants, and transgenic rice display small plant size and low grain yield. OsMADS45 overexpression did not alter the oscillating rhythm of the examined floral regulatory genes but advanced (by approximately 20 days) the up-regulate of two florigens, Hd3a (Heading Date 3a) and RFT1 (RICE FLOWERING LOCUS T1) and suppressed the expression of Hd1 at the juvenile stage. The expression levels of OsMADS14 and OsMADS18, which are two well-known reproductive phase transition markers, were also increased at early developmental stages and are believed to be the major regulators responsible for early flowering in OsMADS45-overexpressing transgenic rice. OsMADS45 overexpression did not influence other floral regulator genes upstream of Hd1 and Ehd1, such as OsGI (OsGIGANTEA), Ehd2/Osld1/RID1 and OsMADS50. CONCLUSION: These results indicate that in transgenic rice, OsMADS45 overexpressing ectopically activates the upstream genes Hd3a and RFT1 at early development stage and up-regulates the expression of OsMADS14 and OsMADS18, which induces early flowering.
ABSTRACT
The incidence and severity of rheumatoid arthritis decline during pregnancy. However, the role of hormones of pregnancy, including estrogens and relaxin, in attenuating the symptoms of rheumatoid arthritis, including joint inflammation and bone destruction is unknown. In rat adjuvant-induced arthritis, a model for rheumatoid arthritis, relaxin in combination with estrogens, reduced joint inflammation and circulating levels of pro-inflammatory, tumor necrosis factor alpha. In addition, relaxin together with estrogens, altered systemic levels of bone remodeling markers receptor activator of nuclear factor-kappa B, its ligand and osteoprotegerin to improve bone health when compared with arthritic controls. In vitro studies using primary rat osteoblasts and an osteoblast cell line showed a similar bon-saving response to treatment with estrogens in combination with relaxin.
Subject(s)
Arthritis, Experimental/drug therapy , Bone Remodeling/drug effects , Estrogens/administration & dosage , Relaxin/administration & dosage , Animals , Arthritis, Experimental/immunology , Bone Remodeling/immunology , Disease Models, Animal , Female , Humans , Osteoblasts/cytology , Osteoblasts/drug effects , Pregnancy , Primary Cell Culture , RatsABSTRACT
The neonatal porcine cervix is sensitive to hormones, including relaxin (RLX), from birth. Whether nursing is required to establish the cervical developmental program or to determine cervical developmental trajectory is unknown. The objective of study 1 was to determine effects of age and nursing on expression of molecular markers and mediators of porcine cervical growth and remodeling from birth to postnatal day (PND) 2 and to document effects of RLX treatment during this period on expression of targeted gene products in nursed vs. replacer-fed gilts. Study 2 was conducted to determine effects of age at first nursing and duration of nursing from birth on expression of targeted transcripts or proteins at PND 14. Nursing supported cervical estrogen receptor-α, vascular endothelial growth factor, matrix metalloproteinase (MMP)9, and antiapoptotic B-cell lymphoma-2 protein expression on PND 2. These proteins were undetectable in replacer-fed gilts. Returning replacer-fed gilts to nursing after PND 2 did not restore cervical expression of these proteins by PND 14. RLX increased (P < 0.05) cervical estrogen receptor-α, vascular endothelial growth factor, and B-cell lymphoma-2 protein in nursed gilts, MMP2 protein in nursed and replacer-fed gilts, and decreased (P < 0.05) pro-MMP9 protein in nursed gilts, and RXFP1 mRNA levels in nursed and replacer-fed gilts at PND 2. Replacer feeding for 2 wk from birth increased (P < 0.05) RXFP1 mRNA levels on PND 14. Results support the lactocrine hypothesis for maternal programming of neonatal tissues. Nursing from birth is required to establish the neonatal cervical developmental program and to maintain cervical developmental trajectory to PND 14.
Subject(s)
Cervix Uteri/drug effects , Cervix Uteri/growth & development , Animals , Animals, Newborn , Cervix Uteri/metabolism , Estrogen Receptor alpha/metabolism , Female , Gene Expression Regulation, Developmental , Immunoblotting , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/metabolism , Polymerase Chain Reaction , Relaxin/pharmacology , Swine , Vascular Endothelial Growth Factor A/metabolismABSTRACT
Rheumatoid arthritis (RA) is characterized by joint inflammation and bone destruction. The receptor activator of nuclear factor-kappa B ligand (RANKL)-osteoprotegerin (OPG) system is important for maintaining the balance between bone resorption and formation. Both serum RANKL/OPG protein and synovial tissue RANKL/OPG mRNA ratios are elevated in patients with RA. Studies indicate that hormones of pregnancy, estrogens and relaxin, administered in combination, reduce circulating (TNF)-α and joint inflammation in a rat adjuvant-induced arthritis (AIA) model of RA. The purpose of this study was to investigate whether relaxin (RLX), alone or in combination with estrogens, regulates the bone remodeling markers RANKL and OPG in vivo and in vitro. Results show that in AIA rats, treatment with relaxin, estradiol valerate (EV) or EV in combination with relaxin had no effect on circulating RANKL. However, EV increased systemic OPG and combined treatment with EV and relaxin further increased circulating OPG in comparison to EV alone. Importantly, the RANKL/OPG protein ratio was lower in rats treated with EV or EV+RLX when compared to arthritic controls. Relaxin in combination with EV decreased local RANKL transcripts, increased OPG mRNA and decreased the RANKL/OPG mRNA ratio in joints of arthritic rats when compared to controls. RLX family peptide receptor 1 (RXFP1) gene expression in joints of AIA rats increased in response to EV and EV+RLX. In parathyroid hormone-pretreated murine UMR 106-01 osteoblast cells, 17-ß-estradiol (E) and E+RLX increased RXFP1 transcripts, while RLX reduced RANKL mRNA and protein expression. However, in vitamin D-treated primary rat osteoblast cells E+RLX increased OPG protein and reduced the RANKL/OPG protein ratio. These results suggest that modulation of the RANKL-OPG system by estrogens and RLX may contribute to their antiarthritic effects on bone during pregnancy.
Subject(s)
Arthritis, Experimental/metabolism , Biomarkers/metabolism , Bone Remodeling , Estrogens/pharmacology , Osteoprotegerin/metabolism , RANK Ligand/metabolism , Relaxin/pharmacology , Animals , Base Sequence , Cell Line , DNA Primers , Female , Mice , RANK Ligand/genetics , Rats , Rats, Inbred Lew , Receptors, G-Protein-Coupled/genetics , Receptors, Peptide/geneticsABSTRACT
Lactocrine communication of milk-borne bioactive factors (MbFs) from mother to offspring through nursing can affect neonatal development with lasting consequences. Relaxin (RLX), a lactocrine-active peptide found in porcine colostrum, stimulates estrogen receptor-α (ESR1) expression required for uterine development shortly after birth (postnatal day=PND 0). Whether other MbFs or cooperative lactocrine mechanisms affect the neonatal uterine developmental program is unknown. To determine the effects of age, nursing, and exogenous RLX on gene expression associated with uterine development, gilts (n=4-5/group) were assigned to nurse ad libitum or to receive milk replacer, with or without exogenous RLX (20 µg/kg BW i.m./6 h for 48 h), from birth to PND 2 when uteri were collected. Body weight and uterine weight increased (P<0.05) similarly from birth to PND 2 in all gilts. However, colostrum consumption was required for normal uterine ESR1, vascular endothelial growth factor (VEGFA), matrix metalloproteinase 9 (MMP9), and RLX receptor (RXFP1) protein and/or transcript expression on PND 2. Uterine ESR1, VEGFA, and MMP9 protein levels were below (P<0.01) the assay sensitivity in replacer-fed gilts. Supplemental RLX increased (P<0.05) uterine ESR1 protein and mRNA in nursed gilts, as well as VEGFA protein in nursed and VEGFA mRNA in both nursed and replacer-fed gilts. RLX treatment did not affect uterine MMP9 mRNA levels. When compared with replacer-fed gilts on PND 2, uterine RXFP1 mRNA was reduced (P<0.05) in nursed gilts and in RLX-supplemented replacer-fed gilts. These results constitute the first evidence that establishment of the neonatal porcine uterine developmental program requires maternal lactocrine support.
Subject(s)
Gene Expression Regulation, Developmental , Milk Proteins/metabolism , Relaxin/metabolism , Signal Transduction , Uterus/metabolism , Age Factors , Analysis of Variance , Animals , Animals, Newborn , Blotting, Western , Body Weight , Estrogen Receptor alpha/genetics , Estrogen Receptor alpha/metabolism , Female , Lactation , Linear Models , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Milk Substitutes , Organ Size , Polymerase Chain Reaction , RNA, Messenger/metabolism , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/metabolism , Relaxin/administration & dosage , Swine , Uterus/growth & development , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolismABSTRACT
A lactocrine mechanism for delivery of maternally derived relaxin (RLX) into the neonatal circulation as a consequence of nursing was proposed for the pig. Immunoreactive RLX was detected in colostrum and in the serum of newborn pigs only if they were allowed to nurse. Milk-borne RLX concentrations are highest during early lactation (9-19 âng/ml), declining to <2 âng/ml by postnatal day 14. Whether milk-borne RLX is bioactive is unknown. Evidence that RLX concentrations in milk are higher than in maternal circulation in several species suggests the mammary gland as a site of local RLX production. It is unknown whether the porcine mammary gland is a source of RLX. Therefore, objectives were to evaluate RLX bioactivity in porcine milk during the first 2 weeks of lactation, identify the form of RLX in porcine milk, and determine whether mammary tissue from early lactation is a source of milk-borne RLX. Milk RLX bioactivity was determined using an in vitro bioassay in which cAMP production by human embryonic kidney (HEK293T) cells transfected with the human RLX receptor (RXFP1) was measured. RLX bioactivity was highest at lactation day (LD) 0, decreasing to undetectable levels by LD 4. Immunoblot analysis of milk proteins revealed an 18 âkDa band, indicating proRLX as the primary form of RLX in porcine milk. ProRLX protein and transcripts were detected in porcine mammary tissue on LD 0 and 7. Results support the lactocrine hypothesis by defining the nature and a potential source for bioactive proRLX in porcine colostrum/milk.
Subject(s)
Milk/chemistry , Relaxin/analysis , Relaxin/physiology , Animals , Biological Assay/methods , Biopsy , Cells, Cultured , Colostrum/chemistry , Colostrum/metabolism , Female , Humans , Lactation/metabolism , Lactation/physiology , Mammary Glands, Animal/metabolism , Mammary Glands, Animal/pathology , Milk/metabolism , Protein Precursors/genetics , Protein Precursors/metabolism , RNA, Messenger/analysis , Relaxin/genetics , Relaxin/metabolism , Swine , Time Factors , Validation Studies as TopicABSTRACT
Disruption of estrogen-sensitive, estrogen receptor (ER)-dependent events during porcine uterine development between birth (postnatal day=PND 0) and PND 14 affects patterns of uterine morphoregulatory gene expression in the neonate with lasting consequences for reproductive success. Uterine capacity for conceptus support is reduced in pregnant adult gilts exposed to estradiol valerate (EV) for 14 days from birth. Objectives here were to determine effects of EV exposure from birth through PND 13 on neonatal uterine and adult endometrial markers of growth, patterning, and remodeling. Targets included the relaxin receptor (RXFP1), estrogen receptor-alpha (ESR1) and vascular endothelial growth factor (VEGFA), morphoregulatory markers HOXA10 and WNT7A, and the matrix metalloproteinases (MMP)2 and MMP9. Gilts were treated daily with EV (50 microg/kg body weight per day, i.m.) or corn oil vehicle from birth through PND 13. Uteri were obtained from neonates on PND 14 and from adults on pregnancy day 12 (PxD 12). In neonates, EV exposure from birth increased uterine RXFP1 gene expression, and both ESR1 and VEGFA proteins. At PxD 12, endometrial RXFP1 mRNA remained elevated, while ESR1 protein was reduced. Early EV treatment decreased neonatal uterine WNT7A, but increased HOXA10 expression. WNT7A expression was reduced in EV-treated adults. Transient EV exposure increased MMP9 transcripts at PND 14, whereas both latent and active MMP9 activity was increased due to early EV treatment in adults on PxD 12. Results support the hypothesis that transient, estrogen-induced disruption of porcine uterine development from birth alters early programming events that lead to functional consequences in the adult.
Subject(s)
Estradiol/analogs & derivatives , Genes, Developmental/drug effects , Parturition/drug effects , Pregnancy, Animal , Sus scrofa , Uterus/drug effects , Uterus/growth & development , Age Factors , Animals , Animals, Newborn , Biomarkers/metabolism , Drug Administration Schedule , Drug Evaluation, Preclinical , Endometrium/drug effects , Endometrium/metabolism , Estradiol/administration & dosage , Estradiol/pharmacology , Estrogen Receptor alpha/genetics , Estrogen Receptor alpha/metabolism , Female , Gene Expression Regulation, Developmental/drug effects , Genes, Developmental/genetics , Parturition/physiology , Pregnancy , Pregnancy, Animal/drug effects , Sexual Maturation/drug effects , Sexual Maturation/genetics , Sus scrofa/genetics , Sus scrofa/growth & development , Sus scrofa/metabolism , Time Factors , Uterus/metabolism , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolismABSTRACT
A lactocrine mechanism for delivery of maternally derived relaxin (RLX) into the neonatal circulation as a consequence of nursing has been proposed for the pig. Consistently, immunoreactive porcine RLX was detected in colostrum as well as in the serum of nursing pigs. Concentrations of porcine RLX in milk are highest during early lactation (9-19 ng/mL) and decline to less than 2 ng/mL by postnatal day 14. However, RLX bioactivity has not been described in porcine milk. Therefore, this study was designed to establish an assay for RLX bioactivity in porcine milk and to determine if milk RLX bioactivity was related to RLX concentrations in milk collected at parturition (lactation day 0) and on lactation day 14. To assess milk RLX bioactivity, an in vitro bioassay using human embryonic kidney (HEK293T) cells transfected with the human RLX receptor (LGR7) was developed. Milk RLX bioactivity was confirmed by documentation of a systematic increase in cAMP production by HEK293T-LGR7 cells in response to increasing volumes of day 0 milk. Addition of lactation day 14 milk, porcine insulin, or human insulin-like growth factor 1 to HEK293T-LGR7 cells, or porcine RLX treatment of nontransfected HEK293T cells, failed to elicit a cAMP response. Western blot analysis of milk proteins revealed an 18-kDa protein band, indicating that pro RLX is the primary form of bioactive RLX in porcine milk. Data support the lactocrine hypothesis and suggest a role for milk-borne pro RLX in porcine neonatal development.
Subject(s)
Milk/chemistry , Relaxin/physiology , Swine/physiology , Animals , Animals, Suckling , Cell Line , Colostrum/chemistry , Cyclic AMP/metabolism , Female , Humans , Insulin/pharmacology , Insulin-Like Growth Factor I/pharmacology , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/physiology , Receptors, Peptide/genetics , Receptors, Peptide/physiology , Relaxin/metabolism , Signal Transduction/drug effectsABSTRACT
Relaxin (RLX), reported to play an important role in cardiovascular remodeling, is linked to activation of matrix metalloproteinases (MMPs). Interruption of the cardiac Wnt/beta-catenin signaling system is reported to have antihypertrophic effects. Thus, the objectives of this study were to determine the effects of RLX on the myocardial Wnt/beta-catenin signaling system and MMP expression in the postnatal day 2 (PND 2) porcine heart. Results showed that myocardial Wnt7a and Wnt4 gene expression at PND 2 decreased following treatment with RLX in vivo from birth, while there was no effect on Wnt5a expression. Immunoreactive myocardial beta-catenin protein was reduced in RLX-treated animals. Zymographic analysis of medium from RLX-treated heart explants showed an increase in pro-MMP-2 but not pro-MMP-9 activity. Western blot analysis indicated that RLX increased myocardial MMP-2 protein compared to controls. Data suggest that the RLX-induced decline in Wnt/beta-catenin expression at PND 2, together with increased MMP-2 activity, may be important for neonatal porcine cardiac remodeling.
Subject(s)
Gene Expression Regulation/drug effects , Matrix Metalloproteinase 2/metabolism , Myocardium/metabolism , Relaxin/pharmacology , Wnt Proteins/metabolism , beta Catenin/metabolism , Animals , Animals, Newborn , Blotting, Western , In Vitro Techniques , Reverse Transcriptase Polymerase Chain Reaction , Swine , Wnt Proteins/genetics , Wnt4 ProteinABSTRACT
Matrix metalloproteinases (MMPs) and relaxin (RLX) are reported to play an important role in tissue remodeling and wound repair. When macrophages populate wound sites, they secrete biologically active substances, including MMPs. The transcription factor NF-kappaB is important in MMP gene regulation in macrophage cells. Thus, a monocyte/macrophage cell line, THP-1, was used to study the molecular mechanism of RLX action on MMP-2 and MMP-9 expression. After 24 h incubation with porcine RLX (100 ng/ml), conditioned media (CM) and THP-1 cells were collected. Gelatin zymography demonstrated an increase in pro-MMP-9 activity in response to RLX in CM, and no significant change in pro-MMP-2 expression was observed. Immunoblot analysis also revealed an increase in pro-MMP-9 in CM from RLX-treated THP-1 cells. Gel EMSA showed that NF-kappaB DNA-binding activity was elevated in THP-1 cells treated with RLX for 10 min and reached a peak at 30 min. The NF-kappaB DNA complex was supershifted using antibodies against NF-kappaB subunits p50 and p65. Increased expression of the p50 and p65 NF-kappaB subunits was also detected in THP-1 cells after RLX treatment. Incubation with RLX (90 min) reduced THP-1 expression of the NF-kappaB inhibitor protein, IkappaB-alpha. Using a specific NF-kappaB inhibitor, pyrrolidine dithiocarmate (PDTC) inhibited nuclear binding of NF-kappaB. Pre-exposure to PDTC suppressed pro-MMP-9 activity and protein levels in RLX-treated THP-1 cells. In conclusion, these data suggest that RLX-induced tissue remodeling through increasing MMP-9 expression is dependent on NF-kappaB activation.
Subject(s)
Matrix Metalloproteinase 9/biosynthesis , Matrix Metalloproteinase 9/drug effects , NF-kappa B/drug effects , NF-kappa B/immunology , Relaxin/pharmacology , Signal Transduction/drug effects , Binding Sites , Cell Line , DNA/immunology , Dose-Response Relationship, Drug , Humans , I-kappa B Proteins/antagonists & inhibitors , I-kappa B Proteins/biosynthesis , Matrix Metalloproteinase 9/immunology , NF-KappaB Inhibitor alpha , Proline/analogs & derivatives , Proline/pharmacology , Relaxin/antagonists & inhibitors , Signal Transduction/immunology , Structure-Activity Relationship , Thiocarbamates/pharmacology , Time FactorsABSTRACT
Mesangial cell apoptosis has been proposed as a means of resolution of glomerular hypercellularity in proliferative forms of glomerular disease. We previously demonstrated that adenosine causes mesangial cell apoptosis by stimulating the A3-type adenosine receptor. This is a G protein-coupled receptor shown to activate kinases involved in apoptotic signaling. In this work, we assessed changes in phosphorylation of the mitogen-activated protein kinase extracellular signal-regulated kinase (ERK)1/2 and in levels of specific pro- and antiapoptotic proteins following exposure of mesangial cells to the A3 adenosine receptor agonist N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA). Cultured mesangial cells were incubated with IB-MECA for 30 minutes and 6, 24, and 48 hours. IB-MECA was used at a concentration (30 microM) that induces a reproducible degree of mesangial cell apoptosis. Changes in ERK1/2 phosphorylation and in protein levels of Bcl-2, Bax, and caspase 3 were assessed by Western blot analysis. IB-MECA markedly increased phosphorylation of ERK1/2. This effect peaked at 5 minutes, dissipated by 20 minutes, and was abolished by the inhibitor of ERK phosphorylation, compound U0126, in a dose-dependent manner. This inhibitor had no effect on the extent of IB-MECA-induced apoptosis. Bcl-2 levels progressively declined, whereas those of Bax and activated caspase 3 increased. These observations indicate that stimulation of the A3-type adenosine receptor causes mesangial cell apoptosis via mechanisms independent of ERK activation. The observations also point to an imbalance in the expression of antiapoptotic (Bcl-2) and proapoptotic (Bax, caspase 3) proteins as a potential mechanism underlying adenosine-induced mesangial cell apoptosis.
Subject(s)
Adenosine/analogs & derivatives , Apoptosis , Glomerular Mesangium/pathology , Receptor, Adenosine A3/metabolism , Signal Transduction , Adenosine/pharmacology , Animals , Apoptosis/drug effects , Butadienes/pharmacology , Caspase 3 , Caspases/metabolism , Cell Line, Transformed , Dose-Response Relationship, Drug , Drug Combinations , Enzyme Inhibitors , Glomerular Mesangium/drug effects , Mice , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Nitriles/pharmacology , Phosphorylation , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptor, Adenosine A3/drug effects , Signal Transduction/drug effects , bcl-2-Associated X ProteinABSTRACT
Matrix metalloproteinase (MMP) and relaxin are important for tissue remodeling and wound repair. Macrophages populate wound sites and secrete MMPs. Nuclear factor kappa B (NF-kappaB) is linked to MMP gene regulation. Thus, a monocyte/macrophage cell line, THP-1, was used to study the mechanism of relaxin's action on MMPs. Relaxin increased MMP-9 protein and activity in THP-1 cell-conditioned media, with no significant change in MMP-2 activity. NF-kappaB DNA binding activity was elevated in response to relaxin, and supershift assay showed activation of both NF-kappaB subunits p50 and p65. Relaxin also reduced NF-kappaB inhibitor protein, IkappaB-alpha. In conclusion, these data suggest that relaxin-induced MMP-9 expression in THP-1 cells involves NF-kappaB activation.